Cargando…

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

BACKGROUND: The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of ezetimibe plus rosuvastatin versus rosuvastatin monotherapy to reduce liver fat using magnetic resonance imaging-derived proton density...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Yongin, Rhee, Hyungjin, Kim, Young-eun, Lee, Minyoung, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Choi, Jin-Young, Lee, Yong-ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935785/ https://www.ncbi.nlm.nih.gov/pubmed/35307033 http://dx.doi.org/10.1186/s12916-022-02288-2

Ejemplares similares

Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2020)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
por: Lee, Yong-ho, et al.
Publicado: (2019)

Corrigenda: Table Correction. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
por: Lee, Yong-ho, et al.
Publicado: (2019)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue
por: Cho, Yongin, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis
por: Hong, Namki, et al.
Publicado: (2018)

Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients
por: Oh, Min Seok, et al.
Publicado: (2011)

Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
por: Lee, Hyeok-Hee, et al.
Publicado: (2020)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
por: Lee, Ji-Yeon, et al.
Publicado: (2019)

Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kwon, Ryuk Jun, et al.
Publicado: (2023)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study
por: Lee, Yong-ho, et al.
Publicado: (2018)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis
por: Kim, Byung Gyu, et al.
Publicado: (2023)

Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial
por: Yu, Chih-Chieh, et al.
Publicado: (2012)

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
por: Seo, Sang Hyun, et al.
Publicado: (2022)

Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea
por: Choi, Hyejung, et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
por: Lee, Byung-Wan, et al.
Publicado: (2020)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis
por: Cho, Yongin, et al.
Publicado: (2019)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
por: NODARI, SAVINA, et al.
Publicado: (2007)

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010)

Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
por: Lee, Yong-ho, et al.
Publicado: (2016)

Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
por: Lee, Ji Young, et al.
Publicado: (2022)

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers
por: Wu, Na-Qiong, et al.
Publicado: (2018)

Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores
por: Lee, Yong-ho, et al.
Publicado: (2014)

Dietary Oleate Has Beneficial Effects on Every Step of Non-Alcoholic Fatty Liver Disease Progression in a Methionine- and Choline-Deficient Diet-Fed Animal Model
por: Lee, Ji Young, et al.
Publicado: (2011)

Adding ezetimibe to statin therapy: latest evidence and clinical implications
por: Vavlukis, Marija, et al.
Publicado: (2018)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
por: Wan, Shuling, et al.
Publicado: (2021)

Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2020)

Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes
por: Lee, Inkuk, et al.
Publicado: (2020)

Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients
por: Cho, Yongin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u9aoj37f8ffei5oafecmc11r71